Welcome to our dedicated page for Greenwich Lifesciences news (Ticker: GLSI), a resource for investors and traders seeking the latest updates and insights on Greenwich Lifesciences stock.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) generates news primarily around the clinical and regulatory progress of GLSI-100, its investigational immunotherapy to prevent breast cancer recurrences, and the Phase III FLAMINGO-01 trial. Company press releases highlight milestones in patient screening and enrollment, preliminary clinical observations, regulatory designations, and trial expansion across the United States and Europe.
Readers following GLSI news can expect updates on FLAMINGO-01, including the number of patients screened, enrollment status in the HLA-A*02 and non-HLA-A*02 arms, and preliminary analyses of recurrence rates, immune responses, and safety. The company has reported that more than 1,000 patients have been screened and that the 250-patient non-HLA-A*02 open label arm is fully enrolled, with early analyses suggesting an approximately 80% reduction in recurrence rate after completion of the primary immunization series. These observations are described by the company as preliminary and subject to change as the trial matures.
News items also cover regulatory developments, such as the U.S. FDA granting Fast Track designation for GLSI-100 in the HLA-A*02 genotype population, and geographic expansion of FLAMINGO-01 into additional European countries, including Ireland, Portugal, Belgium, and Austria, following approvals from European regulators. Corporate strategy communications discuss clinical strategy, financing approaches such as at-the-market offerings, partnering activities, and oversight by the Data Safety Monitoring Board and Steering Committee.
For investors, clinicians, and observers, the GLSI news feed offers a consolidated view of how Greenwich LifeSciences describes the evolution of its lead program, including trial design refinements, interactions with regulators, and key governance decisions disclosed through SEC filings and press releases. Regularly reviewing these updates can help track the company’s reported progress in developing GLSI-100 for HER2-positive breast cancer patients.
Greenwich LifeSciences (Nasdaq: GLSI) has completed the manufacturing of the GP2 active ingredient for its upcoming Phase III clinical trial aimed at preventing breast cancer recurrences. The drug has met all specifications in compliance with current Good Manufacturing Practice (cGMP) and will soon be reformulated and filled into vials. The company also recently completed its IPO, raising substantial funds that will support this critical trial. GP2, already tested in several trials, showed no recurrences in previous studies of HER2/neu positive patients after treatment.
Greenwich LifeSciences announced the closing of its initial public offering, selling 1,260,870 shares at $5.75 each, totaling $7,250,002 in gross proceeds. The offering includes a 45-day option for the underwriter to purchase an additional 189,130 shares. Trading commenced on Nasdaq under the symbol 'GLSI' on September 25, 2020. The company focuses on developing GP2, an immunotherapy aimed at preventing breast cancer recurrence in patients post-surgery. The Phase IIb trial results showed no recurrences after five years in the treated group, highlighting positive clinical outcomes.